Nasus Pharma Ltd.
NSRX
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative powder-based intranasal therapies. The company’s primary focus is addressing acute medical conditions and urgent public health needs, utilizing proprietary microsphere technology to enable rapid, non-invasive drug delivery. Its product portfolio targets critical emergency situations, such as opioid overdose and anaphylactic shock, where immediate intervention is vital. Intranasal administration provides rapid absorption, ease of use, and does not require injection, making treatments more accessible to patients, caregivers, and first responders. Nasus Pharma’s technology has demonstrated significantly enhanced absorption rates compared to traditional solution-based drugs, supporting its relevance in life-threatening scenarios. Headquartered in Israel, the company’s work is particularly significant for advancing care standards in emergency medicine and holds potential for broader applications in the healthcare sector by improving the speed and effectiveness of drug delivery in acute settings.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$6M
▼ -282.2% YoY
Op. Margin
–
ROIC
-165.28%
▼ -125.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▼ -641.7% YoY
Op. Cash Flow (TTM)
-$5M
▼ -639.5% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
Continue Research
Peers
Drug Manufacturers - General · Pick stocks to compare with NSRX
Nasus Pharma (NSRX) in three numbers
Questions about Nasus Pharma
Is Nasus Pharma a high-quality business?
Nasus Pharma scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$4M, and its weakest is return on capital at -165.3%. The Quality tab shows every check against its target.
Does Nasus Pharma (NSRX) pay a dividend?
No. Nasus Pharma (NSRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NSRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.